The Current Ratio as of December 2024 (TTM) for Finch Therapeutics Group, Inc. (FNCH) is 3.87

According to Finch Therapeutics Group, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.87. This represents a change of -30.80% compared to the average of 5.60 of the last 4 quarters.

Finch Therapeutics Group, Inc. (FNCH) Historical Current Ratio (quarterly & annually)

How has FNCH Current Ratio performed in the past?

The mean historical Current Ratio of Finch Therapeutics Group, Inc. over the last ten years is 7.21. The current 3.87 Current Ratio has changed 5.27% with respect to the historical average. Over the past ten years (40 quarters), FNCH's Current Ratio was at its highest in in the June 2021 quarter at 18.58. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Finch Therapeutics Group, Inc. (FNCH) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Finch Therapeutics Group, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Finch Therapeutics Group, Inc. (FNCH) Average Current Ratio

How has FNCH Current Ratio performed in the past?

The current Current Ratio of Finch Therapeutics Group, Inc. (FNCH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Finch Therapeutics Group, Inc. (FNCH) Current Ratio vs. Peers

How is FNCH’s Current Ratio compared to its peers?

Finch Therapeutics Group, Inc.’s Current Ratio is less than Werewolf Therapeutics, Inc. (10.10), less than Edgewise Therapeutics, Inc. (26.35), less than Decibel Therapeutics, Inc. (4.81), less than Celcuity Inc. (10.36), less than C4 Therapeutics, Inc. (6.31), less than Ikena Oncology, Inc. (15.32), less than Design Therapeutics, Inc. (34.61), greater than Xilio Therapeutics, Inc. (1.67), less than Eliem Therapeutics, Inc. (0), less than Monte Rosa Therapeutics, Inc. (6.03), less than Stoke Therapeutics, Inc. (5.09), less than Virax Biolabs Group Limited (25.94), greater than Blue Water Vaccines, Inc. (0.06), greater than Revelation Biosciences, Inc. (1.64), greater than Hillstream BioPharma, Inc. (2.25), less than Kiora Pharmaceuticals, Inc. (8.97), less than Nutriband Inc. (4.96), greater than Quoin Pharmaceuticals, Ltd. (3.02), less than Longeveron Inc. (7.67), less than RenovoRx, Inc. (5.66),

Build a custom stock screener for Finch Therapeutics Group, Inc. (FNCH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Finch Therapeutics Group, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Finch Therapeutics Group, Inc. (FNCH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Finch Therapeutics Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.